Evidence map›Paper›PMID 40950659›Full record

ArticleTranslational cancer research2025

Xiaoming Fang, Xinyu Zhang, Ping Liu, Dan Yu, Andrzej Swierniak, Carl G Maki, Ruichen Gao, Ming Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoming Fang *Department of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.
Xinyu Zhang *Department of Respiratory and Critical Care Medicine, Shiyan People's Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, China.
Ping LiuDepartment of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.
Dan YuDepartment of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.
Andrzej SwierniakDepartment of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Carl G MakiDepartment of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA.
Ruichen GaoDepartment of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.
Ming LiuDepartment of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Nanjing Medical University, The Second People's Hospital of Changzhou, Changzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interferon-stimulated 20-kDa exonuclease-like 2 ( Methods: We used The Cancer Genome Atlas (TCGA) database and immunohistochemistry to assess the expression of Results: Our results demonstrated that Conclusions:

Indexed as

interferon-stimulated 20-kDa exonuclease-like 2 (ISG20L2)Lung adenocarcinoma (LUAD)NK2 homeobox 1 (NKX2-1)prognosisproliferation

Identifiers

PMID40950659
PMCPMC12432785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.